EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Discovery of benzo[c]phenanthridine derivatives with potent activity against multidrug-resistant Mycobacterium tuberculosis

Yi Chu Liang iD, Zhiqi Sun, Chen Lu, Andréanne Lupien, Zhongliang Xu, Stefania Berton iD, Peng Xu, Marcel A Behr iD, Weibo Yang iD, Jim Sun iD

Microbiology Spectrum · 2024

DOI: 10.1128/spectrum.01246-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, 2024. Verfasst von Yi Chu Liang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, University of British Columbia, Vancouver, Canada. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Antitubercular Agents, Microbial Sensitivity Tests, Tuberculosis, Multidrug-Resistant. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canadian Government | Canadian Institutes of Health Research (CIHR), National Sanitarium Association (NSA), STCSM | Program of Shanghai Academic Research Leader (Shanghai Academic Research Leader).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mycobacterium tuberculosis (Mtb), the pathogen responsible for tuberculosis (TB), is the leading cause of bacterial disease-related death worldwide. Current antibiotic regimens for the treatment of TB remain dated and suffer from long treatment times as well as the development of drug resistance. As such, the search for novel chemical modalities that have selective or potent anti-Mtb properties remains an urgent priority, particularly against multidrug-resistant (MDR) Mtb strains. Herein, we design and synthesize 35 novel b enzo[c] p henanthridine d erivatives (BPDs). The two most potent compounds, BPD-6 and BPD-9, accumulated within the bacterial cell and exhibited strong inhibitory activity (MIC 90 ~2 to 10 µM) against multiple Mycobacterium strains while remaining inactive against a range of other Gram-negative and Gram-positive bacteria. BPD-6 and BPD-9 were also effective in reducing Mtb survival within infected macrophages, and BPD-9 reduced the burden of Mycobacterium bovis BCG in the lungs of infected mice. The two BPD compounds displayed comparable efficacy to rifampicin (RIF) against non-replicating Mtb (NR-Mtb). Importantly, BPD-6 and BPD-9 inhibited the growth of multiple MDR Mtb clinical isolates. Generation of BPD-9-resistant mutants identified the involvement of the Mmr efflux pump as an indirect resistance mechanism. The unique specificity of BPDs to Mycobacterium spp. and their efficacy against MDR Mtb isolates suggest a potential novel mechanism of action. The discovery of BPDs provides novel chemical scaffolds for anti-TB drug discovery. IMPORTANCE The emergence of drug-resistant tuberculosis (TB) is a serious global health threat. There remains an urgent need to discover new antibiotics with unique mechanisms of action that are effective against drug-resistant Mycobacterium tuberculosis (Mtb). This study shows that novel semi-synthetic compounds can be derived from natural compounds to produce potent activity against Mtb. Importantly, the identified compounds have narrow spectrum activity against Mycobacterium species, including clinical multidrug-resistant (MDR) strains, are effective in infected macrophages and against non-replicating Mtb (NR-Mtb), and show anti-mycobacterial activity in mice. These new compounds provide promising chemical scaffolds to develop potent anti-Mtb drugs of the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium tuberculosisAntitubercular AgentsMicrobial Sensitivity TestsTuberculosis, Multidrug-ResistantPhenanthridinesDrug Resistance, Multiple, BacterialAnimalsMiceHumansFemaleMacrophages

Stichwörter der Autor:innen

Mycobacterium tuberculosisanti-mycobacterial compoundsbenzophenanthridinemultidrug-resistant TBnatural compoundsnon-replicating bacteriatuberculosis

Substanzen

Antitubercular AgentsPhenanthridines

Autor:innen und Institutionen

  • Department of Microbiology and Immunology, University of British Columbia, Vancouver, Canada.
  • Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Canada.
  • Chinese Academy of Sciences Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai, China.
  • University of Chinese Academy of Sciences, Beijing, China.
  • Infectious Diseases and Immunity in Global Health Program, Research Institute of the McGill University Health Centre, Montréal, Canada.
  • McGill International TB Centre, Montréal, Canada.

ORCID-Profile: Yi Chu Liang, Stefania Berton, Marcel A Behr, Weibo Yang, Jim Sun

Förderung

  • Canadian Government | Canadian Institutes of Health Research (CIHR)
  • National Sanitarium Association (NSA)
  • STCSM | Program of Shanghai Academic Research Leader (Shanghai Academic Research Leader)
  • MOST | National Natural Science Foundation of China (NSFC)

Zitieren

APA

Liang, Y. C., Sun, Z., Lu, C., Lupien, A., Xu, Z., Berton, S., Xu, P., Behr, M. A., Yang, W., & Sun, J. (2024). Discovery of benzo[c]phenanthridine derivatives with potent activity against multidrug-resistant Mycobacterium tuberculosis. Microbiology Spectrum. https://doi.org/10.1128/spectrum.01246-24

Vancouver

Liang YC, Sun Z, Lu C, Lupien A, Xu Z, Berton S, et al. Discovery of benzo[c]phenanthridine derivatives with potent activity against multidrug-resistant Mycobacterium tuberculosis. Microbiology Spectrum. 2024. doi:10.1128/spectrum.01246-24

BibTeX
@article{Liang2024,
  author = {Liang, Yi Chu and Sun, Zhiqi and Lu, Chen and Lupien, Andréanne and Xu, Zhongliang and Berton, Stefania and Xu, Peng and Behr, Marcel A and Yang, Weibo and Sun, Jim},
  title = {Discovery of benzo[c]phenanthridine derivatives with potent activity against multidrug-resistant Mycobacterium tuberculosis},
  journal = {Microbiology Spectrum},
  year = {2024},
  doi = {10.1128/spectrum.01246-24}
}
Kostenlos starten →